Cardamonin Commands the Colonic Metabolite Columbianetin Acetate to Compete Against LPS in Binding HMGB1 in the Kidney, Preventing Lipopolysaccharide‐Induced Renal Tubular Pyroptosis
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT Sepsis‐associated acute kidney injury (SA‐AKI) results in high mortality due to the lack of effective interventions. The current study reports the protective effect of cardamonin (CAD), a member of the chalcone family, against SA‐AKI using a lipopolysaccharide (LPS)‐stimulated mouse model. CAD was administered by gavage to the mice for 1 week prior to the intraperitoneal injection of LPS, showing a dramatic prevention of renal dysfunction and pathological damage, as well as renal inflammation, oxidative stress, and tubular pyroptosis. Surprisingly, CAD was undetectable in the serum but was significantly enriched in the colon. Metabolomic analysis of the colonic content identified that columbianetin acetate (CA) was drastically increased by CAD. Further measurements confirmed the increase of CA levels in both the colonic content and serum. One‐week oral delivery of CA produced a remarkable preventive effect on LPS‐induced AKI in mice. Combination of network pharmacology, molecular docking, and surface plasmon resonance identified high mobility group box 1 (HMGB1) as the primary target of CA. Further investigation found that CA competed with LPS to bind HMGB1, reducing cellular uptake of LPS, stabilizing lysosomes, and mitigating renal tubular cell pyroptosis. The present study may provide CAD and CA as effective nutritional approaches for SA‐AKI intervention.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Cardamonin Commands the Colonic Metabolite Columbianetin Acetate to Compete Against LPS in Binding HMGB1 in the Kidney, Preventing Lipopolysaccharide‐Induced Renal Tubular Pyroptosis
- Date Crossref
- 20/11/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Shandong University Research Center of Translational Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Jinan Central Hospital pays non établi dans la noticeÉtablissement de santé
-
Weifang People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Shandong Provincial Hospital Neurocritical Care Unit pays non établi dans la noticeÉtablissement de santé
-
Shandong First Medical University pays non établi dans la noticeUniversité ou école supérieure
-
School of Public Health Department of Nutrition and Food Hygiene pays non établi dans la noticeUniversité ou école supérieure
-
Shandong Provincial Engineering and Technology Research Center for Food Safety Monitoring and Evaluation Jinan Shandong China pays non établi dans la noticeStructure de recherche
-
Medical Center of Gastrointestinal Surgery pays non établi dans la noticeÉtablissement de santé
Research Center of Translational Medicine — Shandong University, Jinan Central Hospital et Weifang People's Hospital, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.